*The prognostic and predictive value of Organoids from vena porta-derived Single CTCs in patients with primary ColorectAl canceR for development of liver metastases a feasibility study' (OSCAR)

*The prognostic and predictive value of Organoids from vena porta-derived Single CTCs in patients with primary ColorectAl canceR for development of liver metastases a feasibility study' (OSCAR) - OSCAR Trial

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48875

Enrollment

Registered

2018-01-19

Start date

2020-01-14

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bowel Cancer Colon Cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged *18 years; 2. Clinical diagnosis of colorectal carcinoma with synchronous liver metastases; 3. Scheduled resection of the primary tumour or resection of liver metastases with a liver-first approach; 4. Written informed consent.

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
The main study parameter is the number of patients from which viable Organoids can be cultured from CTCs. On the basis of this number prognostic follow up studies can be designed. With a success rate of 70% the study will be proven feasible.	—

Countries

Netherlands

Outcome results